Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Organon & Co. (OGN)

Organon & Co. (OGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability Business Wire - Tue Aug 11, 6:30AM CDT

Healthcare Providers, Healthcare Settings, and Participating Pharmacies Can Now Begin Required Training and Certification in Preparation for MIUDELLA’s Launch Later This Year

OGN : 13.72 (+0.44%)
Organon: Q2 Earnings Snapshot AP - Fri Jul 31, 7:41AM CDT

Organon: Q2 Earnings Snapshot

OGN : 13.72 (+0.44%)
Organon Announces Quarterly Dividend Business Wire - Fri Jul 31, 7:30AM CDT

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company’s Board of Directors declared...

OGN : 13.72 (+0.44%)
New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1 Business Wire - Fri Jul 24, 7:00AM CDT

The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment...

OGN : 13.72 (+0.44%)
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing Business Wire - Thu Jul 16, 6:30AM CDT

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its...

OGN : 13.72 (+0.44%)
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting Business Wire - Tue Jul 7, 7:00AM CDT

New analysis of pooled Phase 3 data will evaluate efficacy and safety of VTAMA cream across age groups in pediatric and adult patients with atopic dermatitis (AD)

OGN : 13.72 (+0.44%)
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? PR Newswire - Thu Jun 25, 12:58PM CDT

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

TBRG : 26.24 (unch)
OGN : 13.72 (+0.44%)
MDV : 18.05 (-0.88%)
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN Business Wire - Wed Jun 24, 1:28PM CDT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Organon & Co. ...

OGN : 13.72 (+0.44%)
Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA Business Wire - Tue Jun 23, 4:30AM CDT

The launch expands Organon’s biosimilars portfolio in Canada to eight products spanning five therapeutic areas

OGN : 13.72 (+0.44%)
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device Business Wire - Mon Jun 22, 6:30AM CDT

This transaction strengthens Organon’s contraception portfolio and expands long-acting reversible options for women

OGN : 13.72 (+0.44%)

Barchart Exclusives

H&R Block Posted Strong Earnings and Boosted Its Dividend by Nearly 10%. What This Means for HRB Stock. Barchart - Thu Aug 13, 6:30PM CDT
H&R Block beat fiscal fourth-quarter estimates, raised its fiscal 2027 outlook, and increased its quarterly dividend by nearly 10% to $0.46 per share, sending the stock up about 16%. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.